A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

DLBCL
Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: Zilovertamab vedotin
BIOLOGICAL: Rituximab
DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Bendamustine
DRUG: Granulocyte Colony-Stimulating Factor (G-CSF)

Sponsor

Merck Sharp & Dohme LLC